Literature DB >> 17237794

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Ronald D Cohn1, Christel van Erp, Jennifer P Habashi, Arshia A Soleimani, Erin C Klein, Matthew T Lisi, Matthew Gamradt, Colette M ap Rhys, Tammy M Holm, Bart L Loeys, Francesco Ramirez, Daniel P Judge, Christopher W Ward, Harry C Dietz.   

Abstract

Skeletal muscle has the ability to achieve rapid repair in response to injury or disease. Many individuals with Marfan syndrome (MFS), caused by a deficiency of extracellular fibrillin-1, exhibit myopathy and often are unable to increase muscle mass despite physical exercise. Evidence suggests that selected manifestations of MFS reflect excessive signaling by transforming growth factor (TGF)-beta (refs. 2,3). TGF-beta is a known inhibitor of terminal differentiation of cultured myoblasts; however, the functional contribution of TGF-beta signaling to disease pathogenesis in various inherited myopathic states in vivo remains unknown. Here we show that increased TGF-beta activity leads to failed muscle regeneration in fibrillin-1-deficient mice. Systemic antagonism of TGF-beta through administration of TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and function in vivo. Moreover, we show TGF-beta-induced failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237794      PMCID: PMC3138130          DOI: 10.1038/nm1536

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  30 in total

1.  Regenerative capacity and the number of satellite cells in soleus muscles of normal and mdx mice.

Authors:  J Reimann; A Irintchev; A Wernig
Journal:  Neuromuscul Disord       Date:  2000-06       Impact factor: 4.296

2.  IL-4 acts as a myoblast recruitment factor during mammalian muscle growth.

Authors:  Valerie Horsley; Katie M Jansen; Stephen T Mills; Grace K Pavlath
Journal:  Cell       Date:  2003-05-16       Impact factor: 41.582

3.  Identification of altered gene expression in skeletal muscles from Duchenne muscular dystrophy patients.

Authors:  A V Tkatchenko; G Piétu; N Cros; L Gannoun-Zaki; C Auffray; J J Léger; C A Dechesne
Journal:  Neuromuscul Disord       Date:  2001-04       Impact factor: 4.296

4.  Functional improvement of dystrophic muscle by myostatin blockade.

Authors:  Sasha Bogdanovich; Thomas O B Krag; Elisabeth R Barton; Linda D Morris; Lisa-Anne Whittemore; Rexford S Ahima; Tejvir S Khurana
Journal:  Nature       Date:  2002-11-28       Impact factor: 49.962

5.  Expression of MyoD and myogenin in dystrophic mice, mdx and dy, during regeneration.

Authors:  Y Jin; N Murakami; Y Saito; Y Goto; K Koishi; I Nonaka
Journal:  Acta Neuropathol       Date:  2000-06       Impact factor: 17.088

6.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.

Authors:  Enid R Neptune; Pamela A Frischmeyer; Dan E Arking; Loretha Myers; Tracie E Bunton; Barbara Gayraud; Francesco Ramirez; Lynn Y Sakai; Harry C Dietz
Journal:  Nat Genet       Date:  2003-02-24       Impact factor: 38.330

7.  Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.

Authors:  D S Lim; S Lutucuta; P Bachireddy; K Youker; A Evans; M Entman; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

8.  Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration.

Authors:  Ronald D Cohn; Michael D Henry; Daniel E Michele; Rita Barresi; Fumiaki Saito; Steven A Moore; Jason D Flanagan; Mark W Skwarchuk; Michael E Robbins; Jerry R Mendell; Roger A Williamson; Kevin P Campbell
Journal:  Cell       Date:  2002-09-06       Impact factor: 41.582

9.  Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.

Authors:  Kathryn R Wagner; Alexandra C McPherron; Nicole Winik; Se-Jin Lee
Journal:  Ann Neurol       Date:  2002-12       Impact factor: 10.422

10.  Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration.

Authors:  Sean C Goetsch; Thomas J Hawke; Teresa D Gallardo; James A Richardson; Daniel J Garry
Journal:  Physiol Genomics       Date:  2003-08-15       Impact factor: 3.107

View more
  284 in total

1.  Dynamics of the skeletal muscle secretome during myoblast differentiation.

Authors:  Jeanette Henningsen; Kristoffer T G Rigbolt; Blagoy Blagoev; Bente Klarlund Pedersen; Irina Kratchmarova
Journal:  Mol Cell Proteomics       Date:  2010-07-14       Impact factor: 5.911

Review 2.  Congenital muscular dystrophies: toward molecular therapeutic interventions.

Authors:  James Collins; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

3.  2006 Curt Stern Award Address. Marfan syndrome: from molecules to medicines.

Authors:  Harry C Dietz
Journal:  Am J Hum Genet       Date:  2007-10       Impact factor: 11.025

4.  The matrix-binding domain of microfibril-associated glycoprotein-1 targets active connective tissue growth factor to a fibroblast-produced extracellular matrix.

Authors:  Justin S Weinbaum; Robert T Tranquillo; Robert P Mecham
Journal:  Macromol Biosci       Date:  2010-11-10       Impact factor: 4.979

5.  Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model.

Authors:  Arul Veerappan; Alicia C Reid; Nathan O'Connor; Rosalia Mora; Jacqueline A Brazin; Racha Estephan; Takashi Kameue; Jie Chen; Diane Felsen; Surya V Seshan; Dix P Poppas; Thomas Maack; Randi B Silver
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

Review 6.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

7.  Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Silvia Smaldone; Gabriella Siciliano; Francesco Ramirez
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

8.  Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.

Authors:  Mark E Lindsay; Dorien Schepers; Nikhita Ajit Bolar; Jefferson J Doyle; Elena Gallo; Justyna Fert-Bober; Marlies J E Kempers; Elliot K Fishman; Yichun Chen; Loretha Myers; Djahita Bjeda; Gretchen Oswald; Abdallah F Elias; Howard P Levy; Britt-Marie Anderlid; Margaret H Yang; Ernie M H F Bongers; Janneke Timmermans; Alan C Braverman; Natalie Canham; Geert R Mortier; Han G Brunner; Peter H Byers; Jennifer Van Eyk; Lut Van Laer; Harry C Dietz; Bart L Loeys
Journal:  Nat Genet       Date:  2012-07-08       Impact factor: 38.330

9.  Fibrillin-containing microfibrils are key signal relay stations for cell function.

Authors:  Karina A Zeyer; Dieter P Reinhardt
Journal:  J Cell Commun Signal       Date:  2015-10-08       Impact factor: 5.782

Review 10.  The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure.

Authors:  John Kuchtey; Rachel W Kuchtey
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-12       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.